-- Corporate Booth to Include Virtual Tour of Myford Late-Stage Clinical and Commercial Biomanufacturing Facility Highlighting Immediately Available 2,000-Liter Scale Bioreactor Capacity --
TUSTIN, Calif., Aug. 28, 2018 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO) (NASDAQ:CDMOP), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient lives by providing high quality development and manufacturing services to biotechnology and pharmaceutical companies, today announced that the company will exhibit at the upcoming 2018 BioProcess International Conference & Exhibition. Avid will host a corporate booth (#938) in the conference’s exhibit hall, where it will showcase the company’s comprehensive range of process development, high quality cGMP clinical and commercial manufacturing services. The 2018 BioProcess International Conference & Exhibition is being held September 4-7, 2018 in Boston, MA.
As part of its exhibit, Avid will provide a virtual tour of the company’s 42,000 square foot state-of-the-art commercial biomanufacturing suite (Myford facility), which is in the unique position of being a validated facility with immediately available 2,000-liter scale bioreactor capacity. The company will also discuss the ongoing expansion of its process development capabilities and laboratories.
The Myford facility, located in Tustin, California, incorporates a variety of cutting-edge, single-use equipment with the goal of ultimately accommodating a fully disposable biomanufacturing process. A wide range of innovative features are incorporated into the facility including monolithic modular clean rooms, dedicated support utilities for each key processing area, and the industry’s most advanced single-use production systems and flexible solutions. Uni-directional process flows separate personnel and materials and provide assurance that the design meets the most stringent regulatory requirements for commercial biologics drug substance manufacturing. This facility complements Avid’s legacy commercial facility, located on the same campus, which continues to be responsible for the manufacture of multiple globally marketed commercial products.
For more information on the 2018 BioProcess International Conference & Exhibition, please visit: https://lifesciences.knect365.com/bioprocessinternational/
About Avid Bioservices, Inc.
Avid Bioservices is a dedicated contract development and manufacturing organization (CDMO) focused on development and cGMP manufacturing of biopharmaceutical products derived from mammalian cell culture. The company provides a comprehensive range of process development, high quality cGMP clinical and commercial manufacturing services for the biotechnology and biopharmaceutical industries. With 25 years of experience producing monoclonal antibodies and recombinant proteins in batch, fed-batch and perfusion modes, Avid's services include cGMP clinical and commercial product manufacturing, purification, bulk packaging, stability testing and regulatory strategy, submission and support. The company also provides a variety of process development activities, including cell line development and optimization, cell culture and feed optimization, analytical methods development and product characterization. www.avidbio.com
Kelly Pisarev LordAvid Bioservices, Inc
Stephanie Diaz (Investors)
Vida Strategic Partners
email@example.comTim Brons (Media)
Vida Strategic Partners
Source: Avid Bioservices, Inc